D.E. Shaw & Co’s Krystal Biotech KRYS Stock Holding History

D.E. Shaw & Co’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.92M	Buy	26,700 +17,300	+184%	+$5.17M	﹤0.01%	1816
2026 Q1	$2.43M	Buy	+9,400	New	+$2.5M	﹤0.01%	2762

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co's KRYS Position: Q2 2026 in Review

D.E. Shaw & Co sold out of Krystal Biotech (KRYS) in Q2 2026, closing a stake of 996 shares — an estimated $298K sold.

D.E. Shaw & Co first reported a position in KRYS in Q2 2021 and held it in 19 quarters. The position peaked at $14.6M in Q1 2024. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

D.E. Shaw & Co reported no remaining Krystal Biotech position as of Q2 2026 after selling out during the quarter.
D.E. Shaw & Co sold 996 Krystal Biotech shares in Q2 2026, an estimated $298K.
D.E. Shaw & Co first reported a position in Krystal Biotech in Q2 2021 and held it in 19 quarters.
D.E. Shaw & Co's Krystal Biotech position peaked at $14.6M in Q1 2024.
424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.